The Role of P16, P53, KI-67 and PD-L1 Immunostaining in Primary Vaginal Cancer.

Eva K Egger,Mateja Condic,Damian J Ralser,Milka Marinova,Alexander Mustea,Florian Recker,Glen Kristiansen,Thore Thiesler

Cancers（2023）

引用 0|浏览15

暂无评分

摘要

P16 expression, absence of lymph- or hemangiosis, nodal negative disease and an age below 64 years show improved survival rates in PVC. Tumoral PD-L1 expression as well as PD-L1 expression on immune cells is frequent in PVC, without impacting survival. Within our study cohort, long-term survivors with recurrent PVC are treated with anti-VEGF and immunotherapy.

查看译文

关键词

anti-VEGF-therapy,immunotherapy,vaginal cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要